Integra LifeSciences Announces First Clinical Uses of Cadence™ Total Ankle System in Europe
PLAINSBORO, N.J., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that the first three procedures using the Integra® Cadence™ Total Ankle System in Europe were successfully completed since July 13, 2016 by Dr. Thibaut Leemrijse, of the Foot and Ankle Institute, Parc Léopold Clinic, Brussels, Belgium. Internationally renowned for his expertise in foot surgery, Dr. Leemrijse and his team are considered leaders in the field of ankle arthroplasty.
"Integra's new Cadence system offers a two-component implant, designed to adapt to a patient's anatomy by providing improved range of motion, intraoperatively," said Dr. Leemrijse. "The instrumentation allows ideal positioning of the implant, and the learning curve for this new device seems short, based on our first cases."
The European introduction of the Cadence system supports Integra's role as a leader in this rapidly expanding market. New and improved designs and advanced surgical education programs, such as the ones developed by Integra, are fueling the growth of the ankle prosthesis segment.
"Our innovative arthroplasty device is an example of the close cooperation between our company and expert surgeons, which seeks to develop devices that can be efficiently implanted in various anatomies," said Stéphane Corp, Integra's Vice President, Orthopedics & Tissue Technologies, for Europe, Middle East and Africa.
The Cadence system's differentiated anatomic design and streamlined surgical technique allow Integra to continue offering a complete set of options to treat the continuum of care in total ankle prosthesis, one of the fastest growing extremities segments.
About Integra
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Company Investors Angela Steinway 609-936-2268 angela.steinway@integralife.com Michael Beaulieu 609-750-2827 michael.beaulieu@integralife.com Media Europe Marie-Anne Girel marie-anne.girel@integralife.com Media U.S. Gianna Sabella 609-775-8553 gianna.sabella@integralife.com